Skip to main content
TipRanks
Go Ultimate75% OFF

CordovaCann (CDVA) AI Stock Analysis

0 Followers
TSE:CDVA

CordovaCann

(CNQX:CDVA)

Select Model
Rating:36Underperform
Price Target:CAD 0.01â–¼(-10.00% Downside)
Action:reiterated
Date:11/14/26

CordovaCann scores poorly, driven primarily by a distressed balance sheet: shareholders' equity of roughly -$7.5M, debt of $5.7M against only $5.8M of total assets, and no meaningful cushion against adversity. Revenue has stalled and gross margins have compressed to the low teens, keeping the company in a net loss position despite an encouraging swing to positive operating profit. Three straight years of positive free cash flow (~$1.1M) are a genuine positive and reduce near-term liquidity risk, but the amounts are too small to repair the capital structure quickly. Technicals reinforce the caution, with the price far below all major moving averages, a negative MACD and extreme beta. With negative earnings and no dividend, valuation provides no offsetting support. This remains a highly speculative, high-risk situation.

Positive Factors
Improving Cash GenerationOperating and free cash flow turned positive in 2024–2026, reversing negative cash generation in 2021–2023. This improves near-term self-funding capacity and, if maintained, could reduce dependence on external capital while supporting operations and investment.
Negative Factors
Weakened Balance SheetNegative equity from 2023–2026, debt of roughly $5.0–$6.4M, and declining assets indicate a weakened capital base. This reduces financial flexibility, raises refinancing risk, and can constrain the company’s ability to fund growth or absorb setbacks.

CordovaCann (CDVA) vs. iShares MSCI Canada ETF (EWC)

-75%-50%-25%0%25%50%75%100%TSE:CDVA-75.00%EWC+21.04%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 1.10M
Dividend Yield
―
Average Volume (3M)
34.18K
Price to Earnings (P/E)
-0.7
Beta (1Y)
3.99
Revenue Growth
-6.27%
EPS Growth
44.49%
Country
Canada
Employees
45
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

CordovaCann Business Overview & Revenue Model

Company Description

CordovaCann Corp. is a company that focuses on various aspects of the cannabis industry, including identifying prospects, securing financing, developing new ventures, and managing operations throughout the entire cannabis value chain. As of February...

CordovaCann Financial Statement Overview

Summary

A mixed but predominantly weak profile. The balance sheet is the critical issue: shareholders' equity is deeply negative at roughly -$7.5M, total assets have shrunk to $5.8M while debt has risen to about $5.7M, leaving essentially no financial flexibility and heavy reliance on lender support. The income statement shows revenue stalling and slipping about 2.7% to $13.4M, with gross margin collapsing to the low teens from roughly a third of sales a few years ago, though operating profit turned positive (~$0.5M) and the net loss narrowed to about $1.5M. Cash flow is the clear bright spot, with three consecutive years of positive operating cash flow and roughly $1.1M of free cash flow on minimal capital spending — but at that scale it would take many years to repair the capital structure.

Income Statement

34Negative

Balance Sheet

12Very Negative

Cash Flow

56Neutral
Financial statement breakdown
BreakdownTTMJun 2026Sep 2025Sep 2024Sep 2023Sep 2022
Income Statement
Total Revenue13.36M13.36M14.25M13.80M13.59M13.53M
Gross Profit1.82M1.82M1.55M4.08M3.86M3.73M
EBITDA936.95K895.86K-817.35K493.74K-4.68M-1.85M
Net Income-1.49M-1.49M-2.69M-1.49M-6.88M-3.96M
Balance Sheet
Total Assets5.81M5.81M6.41M9.55M10.26M16.75M
Cash, Cash Equivalents and Short-Term Investments493.53K493.53K598.20K552.47K248.42K714.83K
Total Debt5.70M5.70M5.00M6.21M6.38M6.08M
Total Liabilities12.86M12.86M11.61M12.15M11.29M10.16M
Stockholders Equity-7.54M-7.54M-5.81M-3.30M-1.72M5.86M
Cash Flow
Free Cash Flow1.14M1.14M1.12M1.49M-1.21M-2.73M
Operating Cash Flow1.14M1.14M1.14M1.49M-452.73K-2.07M
Investing Cash Flow001.55M52.96K-708.88K2.07M
Financing Cash Flow-1.01M-1.01M-2.51M-1.10M-134.36K720.69K

CordovaCann Technical Analysis

Technical Analysis SentimentNegative
Last Price0.01

Price Trends

50DMA0.03Negative
100DMA0.03Negative
200DMA0.03Negative

Market Momentum

MACD-0.00Positive
RSI8.18Positive
STOCH0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CDVA, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 8.18 is Positive, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:CDVA.

CordovaCann Risk Analysis

CordovaCann disclosed 43 risk factors in its most recent earnings report. CordovaCann reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

CordovaCann Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:CDVA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:BBMTSE:BBM44NeutralCAD 4.95M-4.76-332.63%―-36.67%40.54%
TSE:CVGRTSE:CVGR37UnderperformCAD 1.94M-1.4164.32%――-26.62%
TSE:CDVATSE:CDVA36UnderperformCAD 1.10M-0.7323.24%―-6.27%44.49%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%TSE:CDVATSE:BBMTSE:BAMMTSE:CVGRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:CDVA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:CDVACordovaCann Corp0.01-0.03-75.00%
TSE:BBMBlueberries Medical0.01-0.01-50.00%
TSE:BAMMBody & Mind 0.030.000.00%
TSE:CVGRCity View Green Holdings, Inc.0.03-0.06-68.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026